Pascal and Francis Bibliographic Databases

Help

Search results

Your search

is.\*:("1359-6535")

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 1547

  • Page / 62
Export

Selection :

  • and

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trialMUSIIME, Victor; COOK, Adrian; ASIIMWE, Alice R et al.Antiviral therapy (London). 2014, Vol 19, Num 3, pp 269-276, issn 1359-6535, 8 p.Article

Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional studyMARCELLIN, Patrick; ARAMA, Victoria; MORAIS, Edith et al.Antiviral therapy (London). 2014, Vol 19, Num 3, pp 235-243, issn 1359-6535, 9 p.Article

Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral loadTAMAI, Hideyuki; MORI, Yoshiyuki; INOUE, Izumi et al.Antiviral therapy (London). 2014, Vol 19, Num 1, pp 107-115, issn 1359-6535, 9 p.Article

Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patientsRELIQUET, Véronique; CHIROUZE, Catherine; ALLAVENA, Clotilde et al.Antiviral therapy (London). 2014, Vol 19, Num 1, pp 117-123, issn 1359-6535, 7 p.Article

A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapyCENTO, Valeria; LANDONIO, Simona; CECCHERINI-SILBERSTEIN, Francesco et al.Antiviral therapy (London). 2013, Vol 18, Num 4, pp 645-648, issn 1359-6535, 4 p.Article

Clonal analysis of the quasispecies of antiviral― resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovirKARATAYLI, Ersin; IDILMAN, Ramazan; KARATAYLI, Senem C et al.Antiviral therapy (London). 2013, Vol 18, Num 1, pp 77-85, issn 1359-6535, 9 p.Article

Could early antiretroviral therapy entail more risks than benefits in sub―Saharan African HIV―infected adults? A model―based analysisANGLARET, Xavier; SCOTT, Callie A; EHOLIE, Serge et al.Antiviral therapy (London). 2013, Vol 18, Num 1, pp 45-55, issn 1359-6535, 11 p.Article

Does venesection reduce HIV viral load in patients with hereditary haemochromatosis?GREAVES, Daniel E; GRIFFITHS, William Jh; LEVER, Andrew Ml et al.Antiviral therapy (London). 2013, Vol 18, Num 1, pp 135-138, issn 1359-6535, 4 p.Article

Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudineOI-SHAN LO, Angeline; WAI-SUN WONG, Vincent; WONG, Grace Lai-Hung et al.Antiviral therapy (London). 2013, Vol 18, Num 5, pp 671-679, issn 1359-6535, 9 p.Article

Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant womenFAYET-MELLO, Aurélie; BUCLIN, Thierry; TELENTI, Amalia et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 171-182, issn 1359-6535, 12 p.Article

Late diagnosis, delayed presentation and late presentation in HIV: proposed definitions, methodological considerations and health implicationsKOZAK, Michael; ZINSKI, Anne; LEEPER, Connie et al.Antiviral therapy (London). 2013, Vol 18, Num 1, pp 17-23, issn 1359-6535, 7 p.Article

Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patientsROMAUTARSING, Reshmie A; DER LUGT, Jasper Van; GOROWARA, Meena et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 249-252, issn 1359-6535, 4 p.Article

Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kgBORAND, Laurence; LAUREILLARD, Didier; MADEC, Yoann et al.Antiviral therapy (London). 2013, Vol 18, Num 3, pp 419-423, issn 1359-6535, 5 p.Article

Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavirGISH, Robert G; CHANG, Ting-Tsung; LAI, Ching-Lung et al.Antiviral therapy (London). 2013, Vol 18, Num 5, pp 691-698, issn 1359-6535, 8 p.Article

Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173GANDHI, Raiesh T; BOSCH, Ronald J; AGA, Evgenia et al.Antiviral therapy (London). 2013, Vol 18, Num 4, pp 607-613, issn 1359-6535, 7 p.Article

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemiaCICCARELLI, Nicoletta; FABBIANI, Massimiliano; COLAFIGLI, Manuela et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 153-160, issn 1359-6535, 8 p.Article

Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backboneWATERS, Laura; BANSI, Loveleen; ASBOE, David et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 213-219, issn 1359-6535, 7 p.Article

Successful treatment of Epstein―Barr virus encephalitis in the setting of HIV-associated neurocognitive disorder: a diagnostic and therapeutic challengeTREVILLYAN, Janine M; MAHONY, Andrew A; MCLEAN, Catriona et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 257-261, issn 1359-6535, 5 p.Article

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patientsLATHOUWERS, Erkki; DE LA ROSA, Guy; VAN DE CASTEELE, Tom et al.Antiviral therapy (London). 2013, Vol 18, Num 3, pp 289-300, issn 1359-6535, 12 p.Article

Vitamin D deficiency and its relation to bone mineral density and liver fibrosis in HIV―HCV coinfectionEL-MAOUCHE, Diala; MEHTA, Shruti H; SUTCLIFFE, Catherine G et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 237-242, issn 1359-6535, 6 p.Article

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovirBIFANO, Marc; HWANG, Carey; OOSTERHUIS, Berend et al.Antiviral therapy (London). 2013, Vol 18, Num 7, pp 931-940, issn 1359-6535, 10 p.Article

Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/ emtricitabine and abacavir/lamivudineVOURVAHIS, Manoli; DAVIS, John; LANGDON, Grant et al.Antiviral therapy (London). 2013, Vol 18, Num 6, pp 745-754, issn 1359-6535, 10 p.Article

Rate and predictors of carotid artery intima media thickness progression in antiretroviral-naive HIV-infected and uninfected adults: a 48-week matched prospective cohort studyHILEMAN, Corrilynn O; CARMAN, Teresa L; LONGENECKER, Chris T et al.Antiviral therapy (London). 2013, Vol 18, Num 7, pp 921-929, issn 1359-6535, 9 p.Article

Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfectionGRACEY, David M; SNELLING, Paul; McENZIE, Paul et al.Antiviral therapy (London). 2013, Vol 18, Num 7, pp 945-948, issn 1359-6535, 4 p.Article

What do we know about the situation of women living with HIV in Europe?MIRALLES, Celia; MARDARESCU, Mariana; SHERR, Lorraine et al.Antiviral therapy (London). 2013, Vol 18, pp 11-17, issn 1359-6535, 7 p., SUP2Article

  • Page / 62